T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.
Giovanni A BottenYuannyu ZhangFranklin FudaPrasad KoduruOlga K WeinbergTamra L SloneRuifang ZhengKathryn E DickersonJeffrey R GaganWeina ChenPublished in: British journal of haematology (2024)
T/myeloid mixed phenotype acute leukaemia (MPAL) is a rare aggressive acute leukaemia with poorly understood pathogenesis. Herein, we report two cases of T/myeloid MPAL harbouring BCL11B-associated structural variants that activate TLX3 (TLX3::BCL11B-TLX3-activation) by genome sequencing and transcriptomic analyses. Both patients were young males with extramedullary involvement. Cooperative gene alterations characteristic of T/myeloid MPAL and T-lymphoblastic leukaemia (T-ALL) were detected. Both patients achieved initial remission following lineage-matched ALL-based therapy with one patient requiring a lineage-switched myeloid-based therapy. Our study is the first to demonstrate the clinicopathological and genomic features of TLX3::BCL11B-TLX3-activated T/myeloid MPAL and provide insights into leukaemogenesis.
Keyphrases
- bone marrow
- dendritic cells
- end stage renal disease
- acute myeloid leukemia
- liver failure
- chronic kidney disease
- newly diagnosed
- single cell
- copy number
- respiratory failure
- prognostic factors
- drug induced
- gene expression
- stem cells
- case report
- aortic dissection
- mesenchymal stem cells
- middle aged
- patient reported
- cell therapy
- acute respiratory distress syndrome
- smoking cessation